ArticleBMC veterinary research2025
Effects of adding Bacillus coagulans to the diet on diarrhea, gut microbiota, and metabolites in yak.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The role of Bacillus coagulans in enhancing animal growth performance and immune function is increasingly recognized. However, its effects on diarrhea, gut microbiota, and metabolites in yaks in China's high-altitude regions remain unclear. This study randomly divided 20 two-year-old male yaks of similar body weight into two groups of 10 animals each. One group served as the control group (CG) fed a basal diet, while the other group received the basal diet supplemented with 1 g Bacillus coagulans per kg of base concentrate (live bacteria count ≥ 5 × 10⁹ CFU/kg) as the experimental group (CP) for 60 days. The Probiotic supplementation significantly reduced the incidence of diarrhea and diarrhea index in the CP group compared to the CG group (P < 0.05), decreasing by 2.34% and 2.2, respectively. Additionally, CP group levels of IgA, IgM, IgG, IL-10, NOS, and T-Aoc were significantly elevated (p < 0.05) relative to CG. Notably, Bacillus coagulans supplementation significantly increased beneficial gut bacteria (Phascolarctobacterium, Agathobacter, Roseburia) in the CP group while suppressing harmful bacteria (e.g., Clostridium). It also modulated metabolic pathways, promoting the production of anti-inflammatory metabolites such as 5-(4-Methoxybenzylidene)-1,3-thiazolidine-2,4-dione, (8'S)-Latochrome, and N-Lauroyl Tyrosine. Consequently, the CP group exhibited higher levels of short-chain fatty acids (SCFAs), including lactic acid, butyric acid, valeric acid, and propionic acid, compared to the CG group. Ultimately, this enhanced yak immune function and reduced diarrhea incidence. Overall, these results suggest Bacillus coagulans may serve as an effective alternative to antibiotic growth promoters for improving yak diarrhea and gut health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.